Abstract: This paper presents a high-power microwave oscillator using a recursive balanced amplification technique. The proposed architecture is configured by a balanced power amplifier (BPA) with ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Recursion Pharmaceuticals' work could change the way that drugs are developed. Its pipeline features some exciting candidates, and it's partnering with major drugmakers. However, Recursion still needs ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Foreign stocks are beating U.S. ones this year. But many investors are still struggling over where—and how much—to invest outside the U.S.

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

Balanced funds can be an investor’s best friend. If you can handle some ups and downs, up to about a 20% drop in value, and you’re planning to invest for at least 10 years, these “set it and forget it ...

This week, I had to make one of the most difficult decisions of my career: saying goodbye to 20% of the team at Recursion. The process was extraordinarily painful, and the costs were heartbreakingly ...

Shares of Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) are trading higher after the company, in collaboration with MIT, announced the release of Boltz-2, a new open-source AI model designed to predict ...

With all the market ups and downs in 2025, one thing’s clear: diversification still works. After years of leading the pack, US stocks have hit a rough patch thanks to renewed global trade tensions, ...